Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma

C. H. Weaver, B. Zhen, Lee Schwartzberg, R. Leff, M. Magee, L. Geier, K. Deaton, L. Lewkow, C. D. Buckner

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

This study was designed to determine the maximum tolerated dose (MTD) of high-dose melphalan (HDM), with peripheral blood stem cell support, that could be given twice within 90 days to patients with multiple myeloma. Twenty patients received tandem HDM at 160, 180 or 200 mg/m2 and a total of 55 were treated at the estimated MTD of 200 mg/m2. Seventeen of 55 (31%) did not receive cycle 2; six because of low CD34+ cell yields, three because of severe (n = 1) or fatal toxicities (n = 2) and eight for other reasons. The median interval between doses for 38 patients was 70 days (range 41-225). Three of 55 patients (5%) died of treatment-related causes. In patients completing two cycles of HDM, at any dose level, the complete remission rate improved from 15% following cycle 1 to 55% following cycle 2. The probabilities of survival, event-free survival and relapse or progression at 18 months for the 55 patients treated at the MTD were 0.84, 0.76 and 0.20, respectively, with a median follow-up of 19 months (range 9-36) from mobilization chemotherapy. It was concluded that two cycles of HDM, 200 mg/m2, could be administered to approximately 70% of patients under the age of 66 with multiple myeloma in a median interval of 70 days, with improvement in CR rates.

Original languageEnglish (US)
Pages (from-to)245-251
Number of pages7
JournalBone Marrow Transplantation
Volume22
Issue number3
DOIs
StatePublished - Jan 1 1998

Fingerprint

Melphalan
Multiple Myeloma
Maximum Tolerated Dose
Peripheral Blood Stem Cells
Disease-Free Survival
Recurrence
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. / Weaver, C. H.; Zhen, B.; Schwartzberg, Lee; Leff, R.; Magee, M.; Geier, L.; Deaton, K.; Lewkow, L.; Buckner, C. D.

In: Bone Marrow Transplantation, Vol. 22, No. 3, 01.01.1998, p. 245-251.

Research output: Contribution to journalArticle

Weaver, C. H. ; Zhen, B. ; Schwartzberg, Lee ; Leff, R. ; Magee, M. ; Geier, L. ; Deaton, K. ; Lewkow, L. ; Buckner, C. D. / Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. In: Bone Marrow Transplantation. 1998 ; Vol. 22, No. 3. pp. 245-251.
@article{27187ce6facf4a849369c453d39e7b55,
title = "Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma",
abstract = "This study was designed to determine the maximum tolerated dose (MTD) of high-dose melphalan (HDM), with peripheral blood stem cell support, that could be given twice within 90 days to patients with multiple myeloma. Twenty patients received tandem HDM at 160, 180 or 200 mg/m2 and a total of 55 were treated at the estimated MTD of 200 mg/m2. Seventeen of 55 (31{\%}) did not receive cycle 2; six because of low CD34+ cell yields, three because of severe (n = 1) or fatal toxicities (n = 2) and eight for other reasons. The median interval between doses for 38 patients was 70 days (range 41-225). Three of 55 patients (5{\%}) died of treatment-related causes. In patients completing two cycles of HDM, at any dose level, the complete remission rate improved from 15{\%} following cycle 1 to 55{\%} following cycle 2. The probabilities of survival, event-free survival and relapse or progression at 18 months for the 55 patients treated at the MTD were 0.84, 0.76 and 0.20, respectively, with a median follow-up of 19 months (range 9-36) from mobilization chemotherapy. It was concluded that two cycles of HDM, 200 mg/m2, could be administered to approximately 70{\%} of patients under the age of 66 with multiple myeloma in a median interval of 70 days, with improvement in CR rates.",
author = "Weaver, {C. H.} and B. Zhen and Lee Schwartzberg and R. Leff and M. Magee and L. Geier and K. Deaton and L. Lewkow and Buckner, {C. D.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1701324",
language = "English (US)",
volume = "22",
pages = "245--251",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma

AU - Weaver, C. H.

AU - Zhen, B.

AU - Schwartzberg, Lee

AU - Leff, R.

AU - Magee, M.

AU - Geier, L.

AU - Deaton, K.

AU - Lewkow, L.

AU - Buckner, C. D.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - This study was designed to determine the maximum tolerated dose (MTD) of high-dose melphalan (HDM), with peripheral blood stem cell support, that could be given twice within 90 days to patients with multiple myeloma. Twenty patients received tandem HDM at 160, 180 or 200 mg/m2 and a total of 55 were treated at the estimated MTD of 200 mg/m2. Seventeen of 55 (31%) did not receive cycle 2; six because of low CD34+ cell yields, three because of severe (n = 1) or fatal toxicities (n = 2) and eight for other reasons. The median interval between doses for 38 patients was 70 days (range 41-225). Three of 55 patients (5%) died of treatment-related causes. In patients completing two cycles of HDM, at any dose level, the complete remission rate improved from 15% following cycle 1 to 55% following cycle 2. The probabilities of survival, event-free survival and relapse or progression at 18 months for the 55 patients treated at the MTD were 0.84, 0.76 and 0.20, respectively, with a median follow-up of 19 months (range 9-36) from mobilization chemotherapy. It was concluded that two cycles of HDM, 200 mg/m2, could be administered to approximately 70% of patients under the age of 66 with multiple myeloma in a median interval of 70 days, with improvement in CR rates.

AB - This study was designed to determine the maximum tolerated dose (MTD) of high-dose melphalan (HDM), with peripheral blood stem cell support, that could be given twice within 90 days to patients with multiple myeloma. Twenty patients received tandem HDM at 160, 180 or 200 mg/m2 and a total of 55 were treated at the estimated MTD of 200 mg/m2. Seventeen of 55 (31%) did not receive cycle 2; six because of low CD34+ cell yields, three because of severe (n = 1) or fatal toxicities (n = 2) and eight for other reasons. The median interval between doses for 38 patients was 70 days (range 41-225). Three of 55 patients (5%) died of treatment-related causes. In patients completing two cycles of HDM, at any dose level, the complete remission rate improved from 15% following cycle 1 to 55% following cycle 2. The probabilities of survival, event-free survival and relapse or progression at 18 months for the 55 patients treated at the MTD were 0.84, 0.76 and 0.20, respectively, with a median follow-up of 19 months (range 9-36) from mobilization chemotherapy. It was concluded that two cycles of HDM, 200 mg/m2, could be administered to approximately 70% of patients under the age of 66 with multiple myeloma in a median interval of 70 days, with improvement in CR rates.

UR - http://www.scopus.com/inward/record.url?scp=0031827442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031827442&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701324

DO - 10.1038/sj.bmt.1701324

M3 - Article

VL - 22

SP - 245

EP - 251

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -